Valeria Maria Gloria Bruno

List of Publications by Year
in descending order

131 papers	8,097 citations	28190 55 h-index	51492 86 g-index
132 all docs	132 docs citations	132 times ranked	8047 citing authors

#	Article	IF	Citations
1	Perineuronal nets are under the control of type-5 metabotropic glutamate receptors in the developing somatosensory cortex. Translational Psychiatry, 2021, 11, 109.	2.4	5
2	Genetic Deletion of mGlu3 Metabotropic Glutamate Receptors Amplifies Ischemic Brain Damage and Associated Neuroinflammation in Mice. Frontiers in Neurology, 2021, 12, 668877.	1.1	5
3	Behavioural and biochemical responses to methamphetamine are differentially regulated by mGlu2 and mGlu3 metabotropic glutamate receptors in male mice. Neuropharmacology, 2021, 196, 108692.	2.0	8
4	Repeated episodes of transient reduction of oxygen exposure simulating aircraft cabin conditions enhance resilience to stress in mice. European Journal of Neuroscience, 2021, 54, 7109-7124.	1.2	0
5	Upregulation of Tolerogenic Pathways by the Hydrogen Sulfide Donor GYY4137 and Impaired Expression of H2S-Producing Enzymes in Multiple Sclerosis. Antioxidants, 2020, 9, 608.	2.2	9
6	Pharmacological activation of mGlu5 receptors with the positive allosteric modulator VU0360172, modulates thalamic GABAergic transmission. Neuropharmacology, 2020, 178, 108240.	2.0	10
7	The Trace Kynurenine, Cinnabarinic Acid, Displays Potent Antipsychotic-Like Activity in Mice and Its Levels Are Reduced in the Prefrontal Cortex of Individuals Affected by Schizophrenia. Schizophrenia Bulletin, 2020, 46, 1471-1481.	2.3	20
8	The Role of Macrophage Migration Inhibitory Factor in Alzheimerâ€²s Disease: Conventionally Pathogenetic or Unconventionally Protective?. Molecules, 2020, 25, 291.	1.7	31
9	N-Acetylcysteine causes analgesia in a mouse model of painful diabetic neuropathy. Molecular Pain, 2020, 16, 174480692090429.	1.0	14
10	The Dichotomic Role of Macrophage Migration Inhibitory Factor in Neurodegeneration. International Journal of Molecular Sciences, 2020, 21, 3023.	1.8	15
11	Transcriptomic Analysis Reveals Abnormal Expression of Prion Disease Gene Pathway in Brains from Patients with Autism Spectrum Disorders. Brain Sciences, 2020, 10, 200.	1.1	2
12	Targeting mGlu Receptors for Optimization of Antipsychotic Activity and Disease-Modifying Effect in Schizophrenia. Frontiers in Psychiatry, 2019, 10, 49.	1.3	38
13	Targeting metabotropic glutamate receptors in the treatment of epilepsy: rationale and current status. Expert Opinion on Therapeutic Targets, 2019, 23, 341-351.	1.5	37
14	Metabotropic glutamate receptor involvement in the pathophysiology of amyotrophic lateral sclerosis: new potential drug targets for therapeutic applications. Current Opinion in Pharmacology, 2018, 38, 65-71.	1.7	22
15	Functional partnership between mGlu3 and mGlu5 metabotropic glutamate receptors in the central nervous system. Neuropharmacology, 2018, 128, 301-313.	2.0	79
16	Dickkopf-3 Causes Neuroprotection by Inducing Vascular Endothelial Growth Factor. Frontiers in Cellular Neuroscience, 2018, 12, 292.	1.8	13
17	mGlu1 Receptors Monopolize the Synaptic Control of Cerebellar Purkinje Cells by Epigenetically Down-Regulating mGlu5 Receptors. Scientific Reports, 2018, 8, 13361.	1.6	6
18	Cinnabarinic acid and xanthurenic acid: Two kynurenine metabolites that interact with metabotropic glutamate receptors. Neuropharmacology, 2017, 112, 365-372.	2.0	63

#	Article	IF	Citations
19	The impact of metabotropic glutamate receptors into active neurodegenerative processes: A â€œdark sideâ€•in the development of new symptomatic treatments for neurologic and psychiatric disorders. Neuropharmacology, 2017, 115, 180-192.	2.0	62
20	Type-7 metabotropic glutamate receptors negatively regulate Î±1-adrenergic receptor signalling. Neuropharmacology, 2017, 113, 343-353.	2.0	4
21	Analgesia induced by the epigenetic drug, L-acetylcarnitine, outlasts the end of treatment in mouse models of chronic inflammatory and neuropathic pain. Molecular Pain, 2017, 13, 174480691769700.	1.0	21
22	Alterations in the Î±₂Î´ ligand, thrombospondinâ€•1, in a rat model of spontaneous absence epilepsy and in patients with idiopathic/genetic generalized epilepsies. Epilepsia, 2017, 58, 1993-2001.	2.6	8
23	Permissive role for mGlu1 metabotropic glutamate receptors in excitotoxic retinal degeneration. Neuroscience, 2017, 363, 142-149.	1.1	13
24	Expression of the K + /Cl â^’ cotransporter, KCC2, in cerebellar Purkinje cells is regulated by group-I metabotropic glutamate receptors. Neuropharmacology, 2017, 115, 51-59.	2.0	7
25	Dickkopf-3 Upregulates VEGF in Cultured Human Endothelial Cells by Activating Activin Receptor-Like Kinase 1 (ALK1) Pathway. Frontiers in Pharmacology, 2017, 8, 111.	1.6	26
26	Vasorelaxing Action of the Kynurenine Metabolite, Xanthurenic Acid: The Missing Link in Endotoxin-Induced Hypotension?. Frontiers in Pharmacology, 2017, 8, 214.	1.6	33
27	Genetic deletion of mGlu2 metabotropic glutamate receptors improves the short-term outcome of cerebral transient focal ischemia. Molecular Brain, 2017, 10, 39.	1.3	10
28	Xanthurenic Acid Activates mGlu2/3 Metabotropic Glutamate Receptors and is a Potential Trait Marker for Schizophrenia. Scientific Reports, 2016, 5, 17799.	1.6	91
29	Type-1, but Not Type-5, Metabotropic Glutamate Receptors are Coupled to Polyphosphoinositide Hydrolysis in the Retina. Neurochemical Research, 2016, 41, 924-932.	1.6	4
30	Antidepressant activity of fingolimod in mice. Pharmacology Research and Perspectives, 2015, 3, e00135.	1.1	42
31	Targeting type-2 metabotropic glutamate receptors to protect vulnerable hippocampal neurons against ischemic damage. Molecular Brain, 2015, 8, 66.	1.3	22
32	Metabotropic glutamate receptors as drug targets: what's new?. Current Opinion in Pharmacology, 2015, 20, 89-94.	1.7	83
33	5-HT2C serotonin receptor blockade prevents tau protein hyperphosphorylation and corrects the defect in hippocampal synaptic plasticity caused by a combination of environmental stressors in mice. Pharmacological Research, 2015, 99, 258-268.	3.1	18
34	Changes in the expression of genes encoding for mGlu4 and mGlu5 receptors and other regulators of the indirect pathway in acute mouse models of drug-induced parkinsonism. Neuropharmacology, 2015, 95, 50-58.	2.0	6
35	Activation of mGlu3 metabotropic glutamate receptors enhances GDNF and GLT-1 formation in the spinal cord and rescues motor neurons in the SOD-1 mouse model of amyotrophic lateral sclerosis. Neurobiology of Disease, 2015, 74, 126-136.	2.1	41
36	Changes in mGlu5 Receptor-Dependent Synaptic Plasticity and Coupling to Homer Proteins in the Hippocampus of Ube3A Hemizygous Mice Modeling Angelman Syndrome. Journal of Neuroscience, 2014, 34, 4558-4566.	1.7	73

#	Article	IF	Citations
37	Fingolimod protects cultured cortical neurons against excitotoxic death. Pharmacological Research, 2013, 67, 1-9.	3.1	77
38	Dual Effect of 17Î²-Estradiol on NMDA-Induced Neuronal Death: Involvement of Metabotropic Glutamate Receptor 1. Endocrinology, 2012, 153, 5940-5948.	1.4	9
39	Estrogen Receptors and Type 1 Metabotropic Glutamate Receptors Are Interdependent in Protecting Cortical Neurons against Î²-Amyloid Toxicity. Molecular Pharmacology, 2012, 81, 12-20.	1.0	31
40	Cinnabarinic Acid, an Endogenous Metabolite of the Kynurenine Pathway, Activates Type 4 Metabotropic Glutamate Receptors. Molecular Pharmacology, 2012, 81, 643-656.	1.0	67
41	Metabotropic glutamate receptors in neurodegeneration/neuroprotection: Still a hot topic?. Neurochemistry International, 2012, 61, 559-565.	1.9	66
42	N-Acetyl-Cysteine Causes Analgesia by Reinforcing the Endogenous Activation of Type-2 Metabotropic Glutamate Receptors. Molecular Pain, 2012, 8, 1744-8069-8-77.	1.0	42
43	Lack or Inhibition of Dopaminergic Stimulation Induces a Development Increase of Striatal Tyrosine Hydroxylase-Positive Interneurons. PLoS ONE, 2012, 7, e44025.	1.1	13
44	Dysfunction of TGF-Î²1 signaling in Alzheimerâ€™s disease: perspectives for neuroprotection. Cell and Tissue Research, 2012, 347, 291-301.	1.5	96
45	Protective role for type-1 metabotropic glutamate receptors against spike and wave discharges in the WAG/Rij rat model of absence epilepsy. Neuropharmacology, 2011, 60, 1281-1291.	2.0	36
46	Early defect of transforming growth factor Î²1 formation in Huntingtonâ€™s disease. Journal of Cellular and Molecular Medicine, 2011, 15, 555-571.	1.6	64
47	TGF-Î²1 Pathway as a New Target for Neuroprotection in Alzheimer's Disease. CNS Neuroscience and Therapeutics, 2011, 17, 237-249.	1.9	96
48	Induction of the Wnt Antagonist Dickkopf-1 Is Involved in Stress-Induced Hippocampal Damage. PLoS ONE, 2011, 6, e16447.	1.1	56
49	Protective Role for Type 4 Metabotropic Glutamate Receptors against Ischemic Brain Damage. Journal of Cerebral Blood Flow and Metabolism, 2011, 31, 1107-1118.	2.4	33
50	The advent of monoclonal antibodies in the treatment of chronic autoimmune diseases. Neurological Sciences, 2011, 31, 283-288.	0.9	26
51	Targeting Group II Metabotropic Glutamate (mGlu) Receptors for the Treatment of Psychosis Associated with Alzheimer's Disease: Selective Activation of mGlu2 Receptors Amplifies Î²-Amyloid Toxicity in Cultured Neurons, Whereas Dual Activation of mGlu2 and mGlu3 Receptors Is Neuroprotective. Molecular Pharmacology, 2011, 79, 618-626.	1.0	111
52	Metabotropic glutamate receptor-4 modulates adaptive immunity and restrains neuroinflammation. Nature Medicine, 2010, 16, 897-902.	15.2	138
53	d-Aspartate activates mGlu receptors coupled to polyphosphoinositide hydrolysis in neonate rat brain slices. Neuroscience Letters, 2010, 478, 128-130.	1.0	32
54	Activation of mGlu3 Receptors Stimulates the Production of GDNF in Striatal Neurons. PLoS ONE, 2009, 4, e6591.	1.1	48

#	Article	IF	Citations
55	Regulation of Group II Metabotropic Glutamate Receptors by G Protein-Coupled Receptor Kinases: mGlu2 Receptors Are Resistant to Homologous Desensitization. Molecular Pharmacology, 2009, 75, 991-1003.	1.0	45
56	Activation of mGlu2/3 Metabotropic Glutamate Receptors Negatively Regulates the Stimulation of Inositol Phospholipid Hydrolysis Mediated by 5-Hydroxytryptamine_{2A} Serotonin Receptors in the Frontal Cortex of Living Mice. Molecular Pharmacology, 2009, 76, 379-387.	1.0	42
57	Memantine treatment reduces the expression of the K+/Clâˆ’ cotransporter KCC2 in the hippocampus and cerebral cortex, and attenuates behavioural responses mediated by GABAA receptor activation in mice. Brain Research, 2009, 1265, 75-79.	1.1	20
58	Glutamate receptor mGlu2 and mGlu3 knockout striata are dopamine supersensitive, with elevated D2^{High} receptors and marked supersensitivity to the dopamine agonist (+)PHNO. Synapse, 2009, 63, 247-251.	0.6	27
59	Induction of the Wnt Antagonist, Dickkopf-1, Contributes to the Development of Neuronal Death in Models of Brain Focal Ischemia. Journal of Cerebral Blood Flow and Metabolism, 2009, 29, 264-276.	2.4	108
60	Î2-Amyloid Monomers Are Neuroprotective. Journal of Neuroscience, 2009, 29, 10582-10587.	1.7	350
61	Metabotropic Glutamate Receptors in Glial Cells. Neurochemical Research, 2008, 33, 2436-2443.	1.6	110
62	The Wnt Antagonist, Dickkopf-1, as a Target for the Treatment of Neurodegenerative Disorders. Neurochemical Research, 2008, 33, 2401-2406.	1.6	55
63	Enhanced expression of Harvey ras induced by serum deprivation in cultured astrocytes. Journal of Neurochemistry, 2008, 106, 551-559.	2.1	6
64	GABAergic drugs become neurotoxic in cortical neurons pre-exposed to brain-derived neurotrophic factor. Molecular and Cellular Neurosciences, 2008, 37, 312-322.	1.0	7
65	Positive allosteric modulation of metabotropic glutamate 4 (mGlu4) receptors enhances spontaneous and evoked absence seizures. Neuropharmacology, 2008, 54, 344-354.	2.0	50
66	Defective group-II metaboropic glutamate receptors in the hippocampus of spontaneously depressed rats. Neuropharmacology, 2008, 55, 525-531.	2.0	48
67	Switch in the expression of mGlu1 and mGlu5 metabotropic glutamate receptors in the cerebellum of mice developing experimental autoimmune encephalomyelitis and in autoptic cerebellar samples from patients with multiple sclerosis. Neuropharmacology, 2008, 55, 491-499.	2.0	40
68	Enhanced Tau Phosphorylation in the Hippocampus of Mice Treated with 3,4-Methylenedioxymethamphetamine (â€œEcstasyâ€). Journal of Neuroscience, 2008, 28, 3234-3245.	1.7	45
69	Molecular Signalling Mediating the Protective Effect of A1 Adenosine and mGlu3 Metabotropic Glutamate Receptor Activation against Apoptosis by Oxygen/Glucose Deprivation in Cultured Astrocytes. Molecular Pharmacology, 2007, 71, 1369-1380.	1.0	80
70	The Use of Knock-Out Mice Unravels Distinct Roles for mGlu2 and mGlu3 Metabotropic Glutamate Receptors in Mechanisms of Neurodegeneration/Neuroprotection. Journal of Neuroscience, 2007, 27, 8297-8308.	1.7	182
71	Pharmacological activation of mGlu2/3 metabotropic glutamate receptors protects retinal neurons against anoxic damage in the goldfish Carassius auratus. Experimental Eye Research, 2007, 84, 544-552.	1.2	12
72	Induction of the Wnt Inhibitor, Dickkopf-1, Is Associated with Neurodegeneration Related to Temporal Lobe Epilepsy. Epilepsia, 2007, 48, 694-705.	2.6	91

#	Article	IF	Citations
73	Mechanisms involved in the formation of dopamine-induced intracellular bodies within striatal neurons. Journal of Neurochemistry, 2007, 101, 1414-1427.	2.1	49
74	Nanomolar concentrations of anabolicâ€"androgenic steroids amplify excitotoxic neuronal death in mixed mouse cortical cultures. Brain Research, 2007, 1165, 21-29.	1.1	52
75	Metabotropic glutamate receptors: Beyond the regulation of synaptic transmission. Psychoneuroendocrinology, 2007, 32, S40-S45.	1.3	29
76	Pharmacological Activation of mGlu4 Metabotropic Glutamate Receptors Reduces Nigrostriatal Degeneration in Mice Treated with 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine. Journal of Neuroscience, 2006, 26, 7222-7229.	1.7	108
77	Interaction between ephrins/Eph receptors and excitatory amino acid receptors: possible relevance in the regulation of synaptic plasticity and in the pathophysiology of neuronal degeneration. Journal of Neurochemistry, 2006, 98, 1-10.	2.1	46
78	In PC12 Cells Neurotoxicity Induced by Methamphetamine Is Related to Proteasome Inhibition. Annals of the New York Academy of Sciences, 2006, 1074, 174-177.	1.8	13
79	Tic disorders: from pathophysiology to treatment. Journal of Neurology, 2006, 253, 1-15.	1.8	67
80	Insulin Secretion Is Controlled by mGlu5 Metabotropic Glutamate Receptors. Molecular Pharmacology, 2006, 69, 1234-1241.	1.0	54
81	Comparative effects of levobupivacaine and racemic bupivacaine on excitotoxic neuronal death in culture and N-methyl-d-aspartate-induced seizures in mice. European Journal of Pharmacology, 2005, 518, 111-115.	1.7	25
82	Induction of Dickkopf-1, a Negative Modulator of the Wnt Pathway, Is Required for the Development of Ischemic Neuronal Death. Journal of Neuroscience, 2005, 25, 2647-2657.	1.7	127
83	Pharmacological blockade of group II metabotropic glutamate receptors reduces the growth of glioma cells in vivo. Neuro-Oncology, 2005, 7, 236-245.	0.6	100
84	Expression and Function of Metabotropic Glutamate Receptors in Liver. , 2005, , 211-217.		1
85	Interactions between Ephrin-B and Metabotropic Glutamate 1 Receptors in Brain Tissue and Cultured Neurons. Journal of Neuroscience, 2005, 25, 2245-2254.	1.7	39
86	The preferential mGlu2/3 receptor antagonist, LY341495, reduces the frequency of spikeâ€"wave discharges in the WAG/Rij rat model of absence epilepsy. Neuropharmacology, 2005, 49, 89-103.	2.0	53
87	Endogenous Activation of mGlu5 Metabotropic Glutamate Receptors Contributes to the Development of Nigro-Striatal Damage Induced by 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine in Mice. Journal of Neuroscience, 2004, 24, 828-835.	1.7	113
88	Mouse hepatocytes lacking mGlu5 metabotropic glutamate receptors are less sensitive to hypoxic damage. European Journal of Pharmacology, 2004, 497, 25-27.	1.7	19
89	Testosterone amplifies excitotoxic damage of cultured oligodendrocytes. Journal of Neurochemistry, 2004, 88, 1179-1185.	2.1	56
90	Metabotropic Glutamate Receptors and Neurodegeneration. , 2004, , 79-102.		7

#	Article	IF	Citations
91	Pharmacological blockade of mGlu2/3 metabotropic glutamate receptors reduces cell proliferation in cultured human glioma cells. Journal of Neurochemistry, 2003, 84, 1288-1295.	2.1	78
92	Potentiometric, spectroscopic and antioxidant activity studies of SOD mimics containing carnosine. Dalton Transactions, 2003, , 4406-4415.	1.6	66
93	Protective role of group-II metabotropic glutamate receptors against nigro-striatal degeneration induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. Neuropharmacology, 2003, 45, 155-166.	2.0	60
94	(âˆ’)-PHCCC, a positive allosteric modulator of mGluR4: characterization, mechanism of action, and neuroprotection. Neuropharmacology, 2003, 45, 895-906.	2.0	206
95	Neuroprotective Activity of Metabotropic Glutamate Receptor Ligands. Advances in Experimental Medicine and Biology, 2003, 513, 197-223.	0.8	75
96	A novel rat gene encoding a Humaninâ€like peptide endowed with broad neuroprotective activity. FASEB Journal, 2002, 16, 1331-1333.	0.2	59
97	Activation of Group III Metabotropic Glutamate Receptors Inhibits the Production of RANTES in Glial Cell Cultures. Journal of Neuroscience, 2002, 22, 5403-5411.	1.7	79
98	Native group-III metabotropic glutamate receptors are coupled to the mitogen-activated protein kinase/phosphatidylinositol-3-kinase pathways. Journal of Neurochemistry, 2002, 82, 216-223.	2.1	115
99	Selective Blockade of Type-1 Metabotropic Glutamate Receptors Induces Neuroprotection by Enhancing Gabaergic Transmission. Molecular and Cellular Neurosciences, 2001, 17, 1071-1083.	1.0	92
100	Activation of cell-cycle-associated proteins in neuronal death: a mandatory or dispensable path?. Trends in Neurosciences, 2001, 24, 25-31.	4.2	217
101	The mammalian homologue of the novel peptide Bv8 is expressed in the central nervous system and supports neuronal survival by activating the MAP kinase/PI-3-kinase pathways. European Journal of Neuroscience, 2001, 13, 1694-1702.	1.2	75
102	An activity-dependent switch from facilitation to inhibition in the control of excitotoxicity by group I metabotropic glutamate receptors. European Journal of Neuroscience, 2001, 13, 1469-1478.	1.2	62
103	Metabotropic Glutamate Receptor Subtypes as Targets for Neuroprotective Drugs. Journal of Cerebral Blood Flow and Metabolism, 2001, 21, 1013-1033.	2.4	297
104	Synthesis, pharmacokinetics and anticonvulsant activity of 7-chlorokynurenic acid prodrugs. International Journal of Pharmaceutics, 2000, 202, 79-88.	2.6	50
105	Systemically administered d-glucose conjugates of 7-chlorokynurenic acid are centrally available and exert anticonvulsant activity in rodents. Brain Research, 2000, 860, 149-156.	1.1	76
106	Neuroprotective activity of chemokines against N-methyl-d-aspartate or Î²-amyloid-induced toxicity in culture. European Journal of Pharmacology, 2000, 399, 117-121.	1.7	109
107	Selective blockade of metabotropic glutamate receptor subtype 5 is neuroprotective. Neuropharmacology, 2000, 39, 2223-2230.	2.0	119
108	Neuroprotective activity of the potent and selective mGlu1a metabotropic glutamate receptor antagonist, (+)-2-methyl-4 carboxyphenylglycine (LY367385): comparison with LY357366, a broader spectrum antagonist with equal affinity for mGlu1a and mGlu5 receptors. Neuropharmacology, 1999, 38, 199-207.	2.0	120

#	Article	IF	Citations
109	Group-I metabotropic glutamate receptors: hypotheses to explain their dual role in neurotoxicity and neuroprotection. Neuropharmacology, 1999, 38, 1477-1484.	2.0	153
110	Selective activation of group-II metabotropic glutamate receptors is protective against excitotoxic neuronal death. European Journal of Pharmacology, 1998, 356, 271-274.	1.7	44
111	The metabotropic glutamate receptor mGlu5 controls the onset of developmental apoptosis in cultured cerebellar neurons. European Journal of Neuroscience, 1998, 10, 2173-2184.	1.2	55
112	Neuroprotective activity of N-acetylaspartylglutamate in cultured cortical cells. Neuroscience, 1998, 85, 751-757.	1.1	54
113	Chapter 14 Metabotropic glutamate receptors and neurodegeneration. Progress in Brain Research, 1998, 116, 209-221.	0.9	26
114	Metabotropic glutamate receptor agonists stimulate polyphosphoinositide hydrolysis in primary cultures of rat hepatocytes. European Journal of Pharmacology, 1997, 338, R1-R2.	1.7	21
115	The Neuroprotective Activity of Group-II Metabotropic Glutamate Receptors Requires New Protein Synthesis and Involves a Glialâ€"Neuronal Signaling. Journal of Neuroscience, 1997, 17, 1891-1897.	1.7	144
116	Activation of group III metabotropic glutamate receptors is neuroprotective in cortical cultures. European Journal of Pharmacology, 1996, 310, 61-66.	1.7	58
117	Metabotropic glutamate receptors: a new target for the therapy of neurodegenerative disorders?. Trends in Neurosciences, 1996, 19, 267-271.	4.2	391
118	Growth conditions influence DNA methylation in cultured cerebellar granule cells. Developmental Brain Research, 1996, 95, 38-43.	2.1	9
119	Growth conditions differentially affect the constitutive expression of primary response genes in cultured cereballar granule cells. Neurochemical Research, 1995, 20, 611-616.	1.6	10
120	Activation of Class II or III Metabotropic Glutamate Receptors Protects Cultured Cortical Neurons Against Excitotoxic Degeneration. European Journal of Neuroscience, 1995, 7, 1906-1913.	1.2	143
121	Activation of metabotropic glutamate receptors coupled to inositol phospholipid hydrolysis amplifies NMDA-induced neuronal degeneration in cultured cortical cells. Neuropharmacology, 1995, 34, 1089-1098.	2.0	151
122	Activation of Metabotropic Glutamate Receptors Prevents Neuronal Apoptosis in Culture. Journal of Neurochemistry, 1995, 64, 101-108.	2.1	109
123	Protective effect of the metabotropic glutamate receptor agonist, DCG-IV, against excitotoxic neuronal death. European Journal of Pharmacology, 1994, 256, 109-112.	1.7	109
124	Protective action of idebenone against excitotoxic degeneration in cultured cortical neurons. Neuroscience Letters, 1994, 178, 193-196.	1.0	21
125	Thyrotropin releasing hormone (TRH) and its analog, RGH-2202, accelerate maturation of cerebellar neurons in vitro. Developmental Brain Research, 1992, 69, 179-183.	2.1	12
126	Interaction between ÃŸ-N-methylamino- l-alanine and excitatory amino acid receptors in brain slices and neuronal cultures. Brain Research, 1991, 558, 79-86.	1.1	69

#	Article	IF	Citations
127	Excitatory Amino Acids Stimulate Inositol Phospholipid Hydrolysis and Reduce Proliferation in Cultured Astrocytes. Journal of Neurochemistry, 1990, 54, 771-777.	2.1	87
128	Receptors for inositolhexakisphosphate in neurons and anterior pituitary cells. Pharmacological Research, 1990, 22, 83-84.	3.1	2
129	Activation of excitatory amino acid receptors reduces thymidine incorporation and cell proliferation rate in primary cultures of astrocytes. Glia, 1989, 2, 67-69.	2.5	40
130	Inositol Hexakisphosphate (Phytic Acid) Enhances Ca2+Influx and D-[3H]Aspartate Release in Cultured Cerebellar Neurons. Journal of Neurochemistry, 1989, 53, 1026-1030.	2.1	45
131	Gangliosides attenuate NHDA receptor-mediated excitatory amino acid release in cultured cerebellar neurons. Neuropharmacology, 1989, 28, 1283-1286.	2.0	17